Abbott Laboratories reports developments across a global healthcare portfolio that includes diagnostics, medical devices, nutritionals and branded generic medicines. Recurring updates cover cardiovascular technologies such as Ultreon coronary imaging, pulsed field ablation and cardiac pacing systems; diabetes and other medical devices; nutritional products; and diagnostic testing.
Abbott news also includes financial results, guidance, product clearances, clinical data presentations, commercial integrations and portfolio changes. Following the completed Exact Sciences acquisition, oncology diagnostics are a recurring theme, including Cologuard, Oncotype DX, Oncodetect, Riskguard and Cancerguard tests for cancer screening, recurrence risk and treatment support.
Abbott (ABT) launched SimpleScreen CRC in the United States, adding an FDA-approved blood test to its colorectal cancer screening portfolio. Developed and manufactured by Freenome and exclusively commercialized by Abbott, it joins Cologuard Plus for average-risk adults 45 and older. American Cancer Society recommendations limit blood-based screening to people who decline or do not complete preferred screening options.
In a prespecified, U.S. Census-adjusted analysis of PREEMPT CRC, the test showed 81.1% colorectal cancer sensitivity, including 63.5% for Stage I cancer, 13.7% for advanced precancerous lesions, and 90.4% specificity for advanced colorectal neoplasia. Sensitivity measures detection; specificity measures correct negative results. Eligible Medicare Part B patients have no out-of-pocket costs; Medicare Advantage patients may have costs. Positive results require follow-up colonoscopy.
Abbott (ABT) and Berry Street have formed an exclusive partnership to connect Abbott's Lingo over-the-counter continuous glucose monitor with Berry Street's insurance-covered registered dietitian services.
Lingo is designed for adults 18 and older who are not using insulin and want real-time glucose insights to guide nutrition and lifestyle decisions. Berry Street dietitians are specially trained on Lingo and continuous glucose monitors, and provide virtual one-to-one coaching that interprets glucose trends into personalized nutrition recommendations.
Berry Street services are in-network with more than 1,250 health plans, with the company stating that 96% of people pay no out-of-pocket costs, subject to individual coverage. Through this partnership, Berry Street users can obtain Lingo at a 15% discount on 4-week plans, while dietitians gain access to patients' glucose data to support ongoing metabolic health management.
Abbott (ABT) declared a quarterly common dividend of $0.63 per share, marking its 411th consecutive quarterly dividend since 1924. The dividend is payable on November 16, 2026, to shareholders of record as of the close of business on October 15, 2026. Abbott has raised its dividend for 54 consecutive years and is included in the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 straight years.
Abbott (ABT) agreed to pay $385 million on Sept. 14, 2026 to resolve government and civil claims related to its 2022 powdered infant formula recall.
The settlement resolves a Department of Justice investigation and lawsuit, plus actions by certain relators and several state Attorneys General, and does not include any finding of fault or liability. The government has also closed its criminal investigation into the matter. Abbott reports that no unopened, distributed Abbott infant formulas have ever tested positive for Cronobacter sakazakii, and that FDA tests in early March 2022 on unopened product from the homes of affected infants were negative. The CDC later concluded there was “no definitive link” between the Sturgis, Michigan facility and the clinical cases it was investigating.
Abbott (ABT) received U.S. FDA approval on Sept. 8, 2026 for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, to treat atrial fibrillation (AFib), including challenging cases.
The latest generation catheter combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single device, allowing physicians to use either or both during a procedure to tailor therapy and create precise lesions while helping spare surrounding tissue. TactiFlex Duo works with Abbott’s EnSite™ X EP System, which provides high‑resolution 3D cardiac mapping and a PFA Index (PI) tool to assess lesion formation in real time. FDA approval is supported by safety and effectiveness data from the FlexPulse IDE study in paroxysmal AFib. Abbott expects to begin U.S. cases and broader commercial adoption in the coming weeks, adding a fifth major electrophysiology approval to its expanding global PFA‑based portfolio.
Abbott (NYSE: ABT) launched Similac 360 Total Care Made With Whole Milk, described as the first and only commercially sterile, ready-to-feed liquid infant formula made with whole milk in the U.S. The formula combines creamy whole milk with five human milk oligosaccharide prebiotics and is positioned as Similac’s closest formula to breast milk.
According to Abbott, the liquid-only product is non-GMO, free from artificial growth hormones, corn syrup and palm olein oil, and is initially priced at a per-feeding cost similar to Similac 360 Total Care powdered formulas. It is first available at Target and Amazon, with broader U.S. retail rollout planned.
Abbott (NYSE: ABT) announced that its next-generation Amulet 360™ Left Atrial Appendage (LAA) Occluder has received CE Mark for reducing stroke risk in people with non‑valvular atrial fibrillation who are at risk and may not tolerate long‑term blood thinners.
The minimally invasive device uses a redesigned, softer lobe with smaller anchors and an outer disk to improve conformity and dual-seal closure of the LAA. According to Abbott, CE Mark was supported by the 400‑patient VERITAS study, which showed a 99.8% successful implant rate, no reported major complications within seven days, and 93.9% complete LAA closure at 45 days (no leaks >3 mm). Initial cases have been performed in Germany and Denmark, with broader European rollout planned. Amulet 360 remains investigational only in the U.S. and expands Abbott’s electrophysiology and stroke‑prevention portfolio alongside Volt™ PFA, TactiFlex™ Duo and the EnSite™ X mapping system.
Abbott (NYSE: ABT) received U.S. FDA De Novo authorization for Libre Duo 10 Day, described as the world’s first dual glucose‑ketone continuous monitoring system for people with diabetes. The biowearable continuously tracks glucose for daily management while monitoring rising ketone levels in the background to help detect risk of diabetic ketoacidosis (DKA).
Libre Duo 10 Day is the first device to meet both the FDA’s iCGM and new iCGK standards. It is indicated for people with diabetes aged 2 and older, offers up to 10 days of wear, and uses Abbott’s latest U.S. Libre app with integration into the LibreView and LibreLinkUp ecosystem. Abbott plans a U.S. launch later in 2026 and expects connectivity with Beta Bionics’ iLet and Sequel Med Tech’s twiist AID systems by year‑end, and with Insulet, Tandem and MiniMed smart dosing systems in 2027. According to Abbott, a study showed 84.1% of adult sensors and 68.8% of pediatric sensors lasted the full 10 days. Libre Duo systems also hold a CE Mark in Europe.
Abbott (NYSE: ABT) has entered agreements with three law firms to resolve the Gill case and claims involving approximately 2,000 other individuals related to its specialty formulas for preterm infants, for an aggregate payment of about $670 million, instead of paying roughly $600 million for the Gill judgment and accrued interest alone.
According to Abbott, the agreements are a compromise of disputed claims and do not admit liability. The company highlights recent favorable court rulings for preterm formula manufacturers, including a Seventh Circuit decision affirming a pretrial judgment for Abbott, and notes that about 1,700 lawsuits involving roughly 12,700 infants remain pending. Abbott and major health authorities state that preterm infant formulas are regulated, considered necessary for premature infants, and that available evidence does not show they cause NEC.
Abbott (NYSE: ABT) and the National Association of Community Health Centers (NACHC) launched a multi-year NACHC and Abbott Food for Health Initiative to embed “food is medicine” into primary care at more than 1,500 Community Health Centers (CHCs) across the U.S., which collectively serve 52.3 million people.
The initiative introduces three components: a Food for Health Learning Lab for workforce training, a national Food for Health Community of Practice for peer learning, and Food for Health CORE, a voluntary certification recognizing CHCs that build systems and competencies to integrate nutrition into clinical care and chronic disease management.